This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Johnson & Johnson Beats Earnings and Will Lift Dow, Biotech: StockTwits

Stocks in this article: DIA IBB JNJ

NEW YORK (TheStreet) -- Johnson & Johnson  (JNJ) gave the markets a reason to continue Monday's rally. The healthcare giant announced results Tuesday morning that beat Wall Street consensus estimates for earnings per share and revenue.

Wow $jnj crushed it. Congrats longs -- Aleks (@NYCStox) Apr. 15 at 07:48 AM

The results confirmed the growing bullishness on Johnson & Johnson on

Plus, many investors said that J&J's quarterly results, particularly the growth of its pharmaceutical business, could help lift the beaten-down biotech sector. iShares Nasdaq Biotechnology ETF (IBB) has lost 5.2% in the past five days.

$RNN Beat on earnings by $JNJ. Let's see some of the love extend to the Bios today. Best of mornings all! :-) Go $RNN. -- Lynn (@Stocktok) Apr. 15 at 08:06 AM

Johnson & Johnson reported first quarter earnings per share of $1.54 on $18.1 billion in sales. That topped analysts' EPS estimates by 6 cents and sales predictions by $100 million, according to the Analyst Ratings Network. It was the top-trending ticker on early Tuesday morning.

The company increased its full year EPS guidance to between $5.80 to $5.90, excluding special items. The new midpoint of the guidance topped consensus calls for $5.83.

Much of J&J's growth was fueled by medicines. Pharmaceutical sales grew 12.2%, discounting the impact of currency. Drugs to treat arthritis, schizophrenia and myeloma buoyed results. The consumer business actually weighed on growth.

Shares opened more than 2% higher to top $97 per share. Many investors called for more gains. Sentiment on Johnson & Johnson stood at around 86% bullish before the open, according to StockTwits' analytics.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,356.87 +288.00 1.69%
S&P 500 2,012.89 +40.15 2.04%
NASDAQ 4,644.3120 +96.4780 2.12%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs